Tom Reilly Email
Chief Financial Officer . Opthea
South Yarra,
LocationPrimary Email
How to contact Tom Reilly
Join and see Tom's contact info for free!Phone
Current Roles
Employees:
71Revenue:
$11MAbout
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic macular edema (DME), which remain leading causes of vision loss worldwide. \n\nOpthea’s lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D ‘trap’ inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. Sozinibercept has the potential to become the first therapy in 20 years to enable patients with wet AMD to live fuller and healthier lives.Opthea Address
South Yarra, null
AU